SK Biopharmaceuticals Q3 net income down 23.9% to $40.6 mil.
SK Biopharmaceuticals (SK Biopharm), a biopharmaceutical arm of SK Group, on Thursday reported its third-quarter net income of 54.3 billion won ($40.6 million), down 23.9 percent from a year earlier. The biotech company said in a regulatory filing that operating profit for the July-September period rose 65.9 percent on-year to 116.3 billion won. Sales also increased 34.8 percent to 258.4 billion…
We haven't written up this one. The Korea Times has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- SK Biopharmaceuticals Q3 net income down 23.9% to $40.6 mil. koreatimes.co.kr
